To further elucidate the molecular basis underlying decursin’s anti-tumor effects, we examined two malignancy-associated proteins (TP63 and SOX-2) under varying treatment durations (0 h, 24 h, 48 h, and 72 h) and concentrations (0 μM, 10 μM, 20 μM, and 40 μM). This evidence concerns the gene SOX2 and neoplasm.